Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Clinical Study of Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

NCT06956092 is registered in ClinicalTrials.gov with Zhengzhou University as lead sponsor.

NCT NCT06956092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06956092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Clinical Study of Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Lead sponsor
Zhengzhou University
Phase
Phase 4
Overall status
Not yet recruiting
Start date
May 30, 2025
Completion date
December 31, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma (bcl)